Loading clinical trials...
Loading clinical trials...
A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma
Conditions
Interventions
T3011
Locations
7
China
Beijing Cancer Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Jilin Cancer Hospital
Changchun, China
Chengdu Shangjin Nanfu Hospital
Chengdu, China
Fujian Cancer Hospital
Fuzhou, China
The Third People's Hospital of Zhengzhou
Zhengzhou, China
Start Date
January 26, 2024
Primary Completion Date
September 30, 2026
Completion Date
September 30, 2026
Last Updated
January 14, 2026
NCT05969860
NCT05039801
NCT06066138
NCT06264180
NCT07310784
NCT06472661
Lead Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions